Trace amounts of sporadically reappearing HCV RNA can cause infection

Journal of Clinical Investigation

Volumn 124, Issue 8, 2014, Pages 3469-3478

  Veerapu, Naga Suresh ^a,c   Park, Su Hyung ^a   Tully, Damien C ^b   Allen, Todd M ^b   Rehermann, Barbara ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c SHIV NADAR UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA; RIBAVIRIN; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CELLULAR IMMUNITY; CHIMPANZEE; CONTROLLED STUDY; GENE SEQUENCE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; T LYMPHOCYTE; VIREMIA; VIRUS TRANSMISSION; ANIMAL; BLOOD; BLOOD TRANSFUSION; GENETIC VARIABILITY; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; IMMUNOLOGY; ISOLATION AND PURIFICATION; LIVER; PAN TROGLODYTES; PHYLOGENY; PLASMA; TIME; TRANSMISSION; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; BLOOD TRANSFUSION; GENETIC VARIATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER; PAN TROGLODYTES; PHYLOGENY; PLASMA; RIBAVIRIN; RNA, VIRAL; T-LYMPHOCYTES; TIME FACTORS; VIREMIA;

EID: 84905454460     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI73104     Document Type: Article

References (41)

1. Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med. 2013;368(20):1907-1917.
2. Maylin S, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology. 2008;135(3):821-829.
3. Welker MW, Zeuzem S. Occult hepatitis C: how convincing are the current data? Hepatology. 2009;49(2):665-675.
4. Carreno V, Pardo M, Lopez-Alcorocho JM, Rodriguez-Inigo E, Bartolome J, Castillo I. Detection of hepatitis C virus (HCV) RNA in the liver of healthy, anti-HCV antibody-positive, serum HCV RNA-negative patients with normal alanine aminotransferase levels. J Infect Dis. 2006;194(1):53-60.
5. Castillo I, Rodriguez-Inigo E, Lopez-Alcorocho JM, Pardo M, Bartolome J, Carreno V. Hepatitis C virus replicates in the liver of patients who have a sustained response to antiviral treatment. Clin Infect Dis. 2006;43(10):1277- 1283.
6. Radkowski M, et al. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology. 2005;41(1):106-114.
7. McHutchison JG, et al. Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology. 2002;35(3):688-693.
8. Veerapu NS, Raghuraman S, Liang TJ, Heller T, Rehermann B. Sporadic reappearance of minute amounts of hepatitis C virus RNA after successful therapy stimulates cellular immune responses. Gastroenterology. 2011;140(2):676-685.e1.
9. Guedj J, et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci U S A. 2013;110(10):3991-3996.
10. George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology. 2009;49(3):729-738.
11. Morishima C, et al. Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C. Hepatology. 2008;48(5):1412-1419.
12. Lee WM, Polson JE, Carney DS, Sahin B, Gale M, Gale M Jr. Reemergence of hepatitis C virus after 8.5 years in a patient with hypogammaglobulinemia: evidence for an occult viral reservoir. J Infect Dis. 2005;192(6):1088-1092.
13. Lin A, Thadareddy A, Goldstein MJ, Lake-Bakaar G. Immune suppression leading to hepatitis C virus re-emergence after sustained virological response. J Med Virol. 2008;80(10):1720-1722.
14. Fujii H, et al. Relapse of hepatitis C in a pegylatedinterferonalpha-2b plus ribavirin-treated sustained virological responder. Hepatol Res. 2010;40(6):654-660.
15. Koh C, et al. Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy. Aliment Pharmacol Ther. 2013;37(9):887-894.
16. Gruener NH, et al. Late appearance of hepatitis C virus RNA after needlestick injury: necessity for a more intensive follow-up. Infect Control Hosp Epidemiol. 2009;30(3):299-300.
17. US Public Health Service. Updated US Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep. 2001;50(RR-11):1-52.
18. Enomoto N, et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest. 1995;96(1):224-230.
19. Pulverer JE, et al. Temporal and spatial resolution of type I and III interferon responses in vivo. J Virol. 2010;84(17):8626-8638.
20. Makowska Z, Duong FH, Trincucci G, Tough DF, Heim MH. Interferon-beta and interferonlambda signaling is not affected by interferoninduced refractoriness to interferon-alpha in vivo. Hepatology. 2011;53(4):1154-1163.
21. Asabe S, et al. The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol. 2009;83(19):9652-9662.
22. Ralston R, Jacobson I, Scull M. The conundrum of relapse in STAT-C therapy: does HCV play the Red Queen or Rip Van Winkle? Semin Liver Dis. 2011;31(4):410-419.
23. Bauhofer O, Ruggieri A, Schmid B, Schirmacher P, Bartenschlager R. Persistence of HCV in quiescent hepatic cells under conditions of an interferoninduced antiviral response. Gastroenterology. 2012;143(2):429-438.e8.
24. Mizukoshi E, et al. Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV. J Infect Dis. 2008;198(2):203-212.
25. Freeman AJ, et al. Prevalence of production of virus-specific interferon-gamma among seronegative hepatitis C-resistant subjects reporting injection drug use. J Infect Dis. 2004;190(6):1093-1097.
26. Thurairajah PH, et al. Hepatitis C virus (HCV)-specific T cell responses in injection drug users with apparent resistance to HCV infection. J Infect Dis. 2008;198(12):1749-1755.
27. Zeremski M, et al. Hepatitis C virus-specific T-cell immune responses in seronegative injection drug users. J Viral Hepat. 2009;16(1):10-20.
28. Heller T, et al. Occupational exposure to hepatitis C virus: early T-cell responses in the absence of seroconversion in a longitudinal cohort study. J Infect Dis. 2013;208(6):1020-1025.
29. Al-Sherbiny M, et al. Exposure to hepatitis C virus induces cellular immune responses without detectable viremia or seroconversion. Am J Trop Med Hyg. 2005;73(1):44-49.
30. + T cells in hepatitis C virus-exposed healthy seronegative donors. J Immunol. 1999;162(11):6681-6689.
31. Welsh RM, Selin LK. Attrition of memory CD8 T cells. Nature. 2009;459(7247):E3-E4.
32. Bukh J, et al. Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain. J Virol. 2008;82(16):8183-8195.
33. Park SH, et al. Subinfectious hepatitis C virus exposures suppress T cell responses against subsequent acute infection. Nat Med. 2013;19(12):1638-1642.
34. Kwok S, Higuchi R. Avoiding false positives with PCR. Nature. 1989;339(6221):237-238.
35. Takeuchi T, et al. Real-time detection system for quantification of hepatitis C virus genome. Gastroenterology. 1999;116(3):636-642.
36. Liu Z, et al. Accurate representation of the hepatitis C virus quasispecies in 5.2-kilobase amplicons. J Clin Microbiol. 2004;42(9):4223-4229.
37. Henn MR, et al. Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. PLoS Pathog. 2012;8(3):e1002529.
38. Yang X, et al. De novo assembly of highly diverse viral populations. BMC Genomics. 2012;13:475.
39. Macalalad AR, et al. Highly sensitive and specific detection of rare variants in mixed viral populations from massively parallel sequence data. PLoS Comput Biol. 2012;8(3):e1002417.
40. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C (T) method. Nat Protoc. 2008;3(6):1101-1108.
41. Raghuraman S, Park H, Osburn WO, Winkelstein E, Edlin BR, Rehermann B. Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion. J Infect Dis. 2012;205(5):763-771.